Skip to main content
SpringerLink
Log in

PET and PET/CT Imaging in Breast Cancer

  • Chapter
Positron Emission Tomography

  • 2316 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Wahl RL. Clinical oncology update: the emerging role of positron emission tomography. Part 1. In: DeVita VT, Hellman S, Rosenberg S, editors. Principles and Practice of Oncology Updates, vol I. Cedar Knolls, NJ: Lippincott-Raven, 1997:1–18.

    Google Scholar 

  2. Wahl RL. Current status of PET in breast cancer imaging, staging and therapy. Semin Roentgenol 2001;36:250–256.

    Article  PubMed  CAS  Google Scholar 

  3. Brown RS, Wahl RL. Overexpression of Glut-l glucose transporter in human breast cancer: an immunohistochemical study. Cancer (Phila) 1993;72(10):2979–2985.

    Article  PubMed  CAS  Google Scholar 

  4. Brown RS, Leung JY, Fisher S, Frey KA, Ethier SF, Wahl RL. Intratumoral distribution of tritiated-FDG in breast carcinoma: correlation between glut-l expression and FDG uptake. J Nucl Med 1996;37(6):1042–1047.

    PubMed  CAS  Google Scholar 

  5. Bos R, van Der Hoeven JJ, van Der Wall E, van Der Groep P, van Diest PJ, Comans EF, et al. Biologic correlates of (18) fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 2002;20(2):379–387.

    Article  PubMed  CAS  Google Scholar 

  6. Buck A, Schirrmeister H, Kuhn T, Shen C, Kalker T, Kotzerke J, et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging 2002;29(10):1317–1323.

    Article  PubMed  CAS  Google Scholar 

  7. Beaney RP, Lammertsma AA, Jones T, McKenzie CG, Halnan KE. Positron emission tomography for in-vivo measurement of regional blood /low, oxygen utilisation, and blood volume in patients with breast carcinoma. Lancet 1984;1(8369):131–134.

    Article  PubMed  CAS  Google Scholar 

  8. Wilson CB, Lammertsma AA, McKenzie CG, Sikora K, Jones T. Measurements of blood /low and exchanging water space in breast tumors using positron emission tomography: a rapid and noninvasive dynamic method. Cancer Res 1992;52(6):1592–1597.

    PubMed  CAS  Google Scholar 

  9. Wahl RL, Zasadny K, Koeppe RA, Mangner T, Mintun MA, Lee KS et al. Initial evaluation of Cu-62PTSM as a tumor blood /low agent in man: comparison studies with O-15 water. J Nucl Med 1993;34(5):224P (abstract).

    Google Scholar 

  10. Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Charlop A, Lawton TJ, et al. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med. 2002;43(4):500–509.

    PubMed  Google Scholar 

  11. Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Schubert EK, Tseng J, et al. Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nucl Med 2003;44(11):1806–1814.

    PubMed  Google Scholar 

  12. Zasadny KR, Tatsumi M, Wahl RL. FDG metabolism and uptake versus blood flow in women with untreated primary breast cancers. Eur J Nucl Med Mol Imaging 2003;30(2):274–280.

    Article  PubMed  CAS  Google Scholar 

  13. Mintun MA, Welch MJ, Siegel BA, Mathias CJ, Brodack JW, McGuire AH, et al. Breast cancer: PET imaging of estrogen receptors. Radiology 1988;169:45–48.

    PubMed  CAS  Google Scholar 

  14. McGuire AH, Dehdashti F, Siegel BA, Lyss AP, Brodack JW, Mathias CJ, et al. Positron tomographic assessment of 16 alpha-[18F]-fluoro-17 beta-estradiol uptake in metastatic breast carcinoma. J Nucl Med 1991;32(8):1526–1531.

    PubMed  CAS  Google Scholar 

  15. Minn H, Soini I. [18F]Fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer. Eur J Nucl Med 1989;15(2):61–66.

    Article  PubMed  CAS  Google Scholar 

  16. Wahl RL, Cody RL, Hutchins GD, Kuhl DE. PET imaging of breast cancer with 18-FDG. Radiology 1989;173:419.

    Google Scholar 

  17. Kubota K, Matsuzawa T, Amemiya A, Kondo M, Fujiwara T, Watanuki S, et al. Imaging of breast cancer with [18F]-fluorodeoxyglucose and positron emission tomography. J Comput Assist Tomogr 1989;13(6):1097–1098.

    PubMed  CAS  Google Scholar 

  18. Wahl RL, Cody R, Hutchins GD, Mudgett E. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analog 2-[18F]-fluorodeoxy-2-D-glucose (FDG). Radiology 1991;179:765–770.

    PubMed  CAS  Google Scholar 

  19. Wahl RL, Henry CA, Ethier SF. Serum glucose: effects on tumor and normal tissue accumulation of 2-[18F]-fluoro-2-deoxy-Dglucose in rodents with mammary carcinoma. Radiology 1992;183(3):643–647.

    PubMed  CAS  Google Scholar 

  20. Lindholm P, Minn H, Leskinen-Kallio S, Bergman J, Ruotsalainen U, Joensuu H. Influence of the blood glucose concentration on FDG uptake in cancer: a PET study. J Nucl Med 1993;34(1):1–6.

    PubMed  CAS  Google Scholar 

  21. Hoh CK, Hawkins RA, Glaspy JA, Dahlbom M, Tse NY, Hoffman EJ, et al. Cancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy-D-glucose. J Comput Assist Tomogr 1993;17(4):582–589.

    PubMed  CAS  Google Scholar 

  22. Nieweg OE, Kim EE, Wong WH, Broussard WF, Singletary SE, Hortobagyi GN, et al. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer (Phila) 1993;71(12):3920–3925.

    Article  PubMed  CAS  Google Scholar 

  23. Adler LP, Crowe JP, al-Kaisi NK, Sufishine JL. Evaluation of breast masses and axillary lymph nodes with [18F]-2-deoxy-2-fluoro-Dglucose PET. Radiology 1993;187(3):743–750.

    PubMed  CAS  Google Scholar 

  24. Dehdashti F, Mortimer JE, Siegel BA, Griffeth LK, Bonasera TJ, et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med 1995;36:1766–1774.

    PubMed  CAS  Google Scholar 

  25. Bassa P, Kim EE, Inoue T, Wong FCL, Korkmaz M, et al. Evaluation of preoperative chemotherapy using PET with fluorine-18 fluorodeoxyglucose in breast cancer. J Nucl Med 1996;37:931–938.

    PubMed  CAS  Google Scholar 

  26. Avril N, Dose J, Janicke DF, Bense S, Ziegler S, et al. Metabolic characterization of breast tumors with positron emission tomography using 18F-fluorodeoxyglucose. J Clin Oncol 1996;14:1848–1857.

    PubMed  CAS  Google Scholar 

  27. Avril N, Rose CA, Schelling M, Dose J, Kuhn W, Bense S, et al. Breast imaging with positron emission tomography and fluorine-18-fluorodeoxyglucose: use and limitations. J Clin Oncol 2000;18(20):3495–3502.

    PubMed  CAS  Google Scholar 

  28. Yutani K, Shiba E, Kusuoka H, Tatsumi M, Uehara T, Taguchi T, et al. Comparison of FDG-PET with MIBI-SPECT in the detection of breast cancer and axillary lymph node metastasis. J Comput Assist Tomogr 2000;24(2):274–280.

    Article  PubMed  CAS  Google Scholar 

  29. Ishimori T, Patel PV, Wahl RL. Detection of unexpected additional primary malignancies with PET/CT. J Nucl Med 2005;46(5):752–757.

    PubMed  Google Scholar 

  30. Wahl RL, Helvie MA, Chang AE, Andersson I. Detection of breast cancer in women after augmentation mammoplasty using positron emission tomography: initial clinical evaluation. J Nucl Med 1994;35:872–875.

    PubMed  CAS  Google Scholar 

  31. Noh DY, Yun IJ, Kang HS, Kim YC, Cim IS, Chung JK, et al. Detection of cancer in augmented breasts by positron emission tomography. Eur J Surg 1999;165(9):847–851.

    Article  PubMed  CAS  Google Scholar 

  32. Walter C, Scheidhauer K, Goering UJ, Theissen P, Kugel H, Krahe T, Pietrzyk U. Clinical and diagnostic value of preoperative MR mammography and FDG-PET in suspicious breast lesions. Eur Radiol 2003;13(7):1651–1656.

    Article  PubMed  CAS  Google Scholar 

  33. Goerres GW, Michel SC, Fehr MK, Kaim AH, Steinert HC, Seifert B, et al. Follow-up of women with breast cancer: comparison between MRI and FDG-PET. Eur Radiol 2003;13(7):1634–1644.

    Article  Google Scholar 

  34. Semple SI, Gilbert FJ, Redpath TW, Staff RT, Ahearn TS, Welch AE, et al. The relationship between vascular and metabolic characteristics of primary breast tumours. Eur Radiol 2004;14(11):2038–2045.

    Article  PubMed  Google Scholar 

  35. Leskinen-Kallio S, Nagren K, Lehikoinen P, Ruotsalainen U, Joensuu H. Uptake of llC-methionine in breast cancer studied by PET. An association with the size of S-phase fraction. Br J Cancer 1991;64(6):1121–1124.

    PubMed  CAS  Google Scholar 

  36. Levine EA, Freimanis RI, Perrier ND, Morton K, Lesko NM, Bergman S, et al. Positron emission mammography: initial clinical results. Ann Surg Oncol 2003;10(1):86–91.

    Article  PubMed  Google Scholar 

  37. Raylman RR, Majewski S, Wojcik R, Weisenberger AG, Kross B, Popov V, et al. The potential role of positron emission mammography for detection of breast cancer. A phantom study. Med Phys 2000;27(8):1943–1954.

    Article  PubMed  CAS  Google Scholar 

  38. Gagnon JH, Murthy K, Aznar M, Bergman AM, Thompson CI, Robar JL, et al. Positron emission mammographic instrument: initial results. Radiology 2000;215(1):280–285.

    PubMed  Google Scholar 

  39. Doshi NK, Shao Y, Silverman RW, Cherry SR. Design and evaluation of an LSO PET detector for breast cancer imaging. Med Phys 2000;27(7):1535–1543.

    Article  PubMed  CAS  Google Scholar 

  40. Bergman AM, Thompson CJ, Murthy K, Robar JL, Clancy RL, English MJ. Technique to obtain positron emission mammography images in registration with X-ray mammograms. Med Phys 1998;25(11):2119–2129.

    Article  PubMed  CAS  Google Scholar 

  41. Weinberg IN, Beylin D, Zavarzin V, Yarnall S, Stepanov PY, Anashkin E, et al. Positron emission mammography: high-resolution biochemical breast imaging. Recent studies of 16 patients with 18 lesions. Technol Cancer Res Treat 2005;4(1):55–60.

    PubMed  Google Scholar 

  42. Smith MF, Raylman RR, Majewski S, Weisenberger AG. Positron emission mammography with tomographic acquisition using dual planar detectors: initial evaluations. Phys Med Biol 2004;49(11):2437–2452.

    Article  PubMed  Google Scholar 

  43. Rosen EL, Turkington TG, Soo MS, Baker JA, Coleman RE. Detection of primary breast carcinoma with a dedicated, large-field-of-view FDG-PET mammography device: initial experience. Radiology 2005;234(2):527–534.

    PubMed  Google Scholar 

  44. Wahl RL, Kaminski MS, Ethier SP, Hutchins GD. The potential of 2-deoxy-2[18F]fluoro-D-glucose (FDG) for the detection of tumor involvement in lymph nodes. J Nucl Med 1990;31(11):1831–1835.

    PubMed  CAS  Google Scholar 

  45. Wahl RL, Cody RL, August D. Initial evaluation of FDG PET for the staging of the axilla in newly diagnosed breast carcinoma patients. J Nucl Med 1991;32(5):981.

    Google Scholar 

  46. Tse NY, Hoh CK, Hawkins RA, Zinner MJ, Dahlbom M, Choi Y, et al. The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. Ann Surg 1992;216(1):27–34.

    PubMed  CAS  Google Scholar 

  47. Adler LP, Faulhaber PF, Schnur KC, Al-Kasi NL, Shenk RR. Axillary lymph node metastases: screening with [F-18] 2-deoxy-2-fluoro-Dglucose (FDG) PET. Radiology 1997;203:323–327.

    PubMed  CAS  Google Scholar 

  48. Avril N, Dose J, Janicke F, Ziegler S, Romer W, Weber W, et al Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. J Natl Cancer Inst 1996;88(17):1204–1209.

    PubMed  CAS  Google Scholar 

  49. Utech O, Young CS, Winter PF. Prospective evaluation of fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry. Eur J Nucl Med 1996;23(12):1588–1593.

    Article  PubMed  CAS  Google Scholar 

  50. Yutani K, Shiba E, Kusuoka H, Tatsumi M, Uehara T, Taguchi T, et al. Comparison of FDG-PET with MIBI-SPECT in the detection of breast cancer and axillary lymph node metastasis. J Comput Assist Tomogr 2000;24(2):274–280.

    Article  PubMed  CAS  Google Scholar 

  51. Crippa F, Leutner M, Belli F, Gallino F, Greco M, Pilotti S, et al. Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma. J Nucl Med 2000;41(9):1491–1494.

    PubMed  CAS  Google Scholar 

  52. Wahl RL, Siegel BA, Coleman RE, Gatsonis CG, PET Study Group. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group. J Clin Oncol 2004; 22(2):277–285.

    Article  PubMed  Google Scholar 

  53. Lovrics PJ, Chen V, Coates G, Cornacchi SD, Goldsmith CH, Law C, et al. A prospective evaluation of positron emission tomography scanning, sentinel lymph node biopsy, and standard axillary dissection for axillary staging in patients with early stage breast cancer. Ann Surg Oncol 2004;11(9):846–853.

    Article  PubMed  Google Scholar 

  54. Bellon JR, Livingston RB, Eubank WB, Gralow JR, Ellis GK, Dunnwald LK, Mankoff DA. Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer (LABC). Am J Clin Oncol 2004;27(4):407–410.

    Article  PubMed  Google Scholar 

  55. Trampal C, Sorensen J, Engler H, Langstrom B. 18F-FDG whole body positron emission tomography (PET) in the detection of unknown primary tumors. Clin Posit Imaging 2000;3(4):160.

    Article  Google Scholar 

  56. Scoggins CR, Vitola JV, Sandler MP, Atkinson JB, Frexes-Steed M. Occult breast carcinoma presenting as an axillary mass. Am Surg 1999;65(1):1–5.

    PubMed  CAS  Google Scholar 

  57. Lonneux M, Reffad A. Metastases from unknown primary tumor. PET-FDG as initial diagnostic procedure? Clin Posit Imaging 2000;3(4):137–141.

    Article  Google Scholar 

  58. Bohuslavizki KH, Klutmann S, Kroger S, Sonnemann U, Buchert R, Werner JA, et al. FDG PET detection of unknown primary tumors. J Nucl Med 2000;41(5):816–822.

    PubMed  CAS  Google Scholar 

  59. Inoue T, Yutani K, Taguchi T, Tamaki Y, Shiba E, Noguchi S. Preoperative evaluation of prognosis in breast cancer patients by [(18)F]2-deoxy-2-fluoro-D-glucose-positron emission tomography. J Cancer Res Clin Oncol 2004;130(5):273–278.

    Article  PubMed  Google Scholar 

  60. Torizuka T, Zasadny KR, Recker B, Wahl RL. Untreated primary lung and breast cancers: correlation between F-18 FDG kinetic rate constants and findings of in vitro studies. Radiology 1998;207(3):767–774.

    PubMed  CAS  Google Scholar 

  61. Cook GJ, Fogelman I. Skeletal metastases from breast cancer: imaging with nuclear medicine. Semin Nucl Med 1999;29(1):69–79.

    Article  PubMed  CAS  Google Scholar 

  62. Kao CH, Hsieh JF, Tsai SC, Ho YJ, Yen RF. Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases. Anticancer Res 2000;20(3B):2189–2192.

    PubMed  CAS  Google Scholar 

  63. Gallowitsch HJ, Kresnik E, Gasser J, Kumnig G, Igerc I, Mikosch P, Lind P. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging. Invest Radiol 2003;38(5):250–256.

    Article  PubMed  Google Scholar 

  64. Yang SN, Liang JA, Lin FJ, Kao CH, Lin CC, Lee CC. Comparing whole body (18)F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer. J Cancer Res Clin Oncol 2002;128(6):325–328.

    Article  PubMed  CAS  Google Scholar 

  65. Stafford SE, Gralow JR, Schubert EK, Rinn KJ, Dunnwald LK, Livingston RB, Mankoff DA. Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy. Acad Radiol 2002;9(8):913–921.

    Article  PubMed  Google Scholar 

  66. Uematsu T, Yuen S, Yukisawa S, Aramaki T, Morimoto N, Endo M, et al. Comparison of FDG PET and SPECT for detection of bone metastases in breast cancer. AJR Am J Roentgenol 2005;184(4):1266–1273.

    PubMed  Google Scholar 

  67. Fogelman I, Cook G, Israel O, Van der Wall H. Positron emission tomography and bone metastases. Semin Nucl Med 2005;35(2):135–142.

    Article  PubMed  Google Scholar 

  68. Schirrmeister H, Guhlmann A, Kotzerke J, Santjohanser C, Kuhn T, Kreienberg R, et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol 1999;17(8):2381–2389.

    PubMed  CAS  Google Scholar 

  69. Gabelmann A, Reske SN, Hetzel M. Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med 2001;42(12):1800–1804.

    PubMed  Google Scholar 

  70. Rostom AY, Powe J, Kandil A, Ezzat A, Bakheet S, el-Khwsky F, et al. Positron emission tomography in breast cancer: a clinicopathological correlation of results. Br J Radiol 1999;72(863):1064–1068.

    PubMed  CAS  Google Scholar 

  71. Wald JJ, Wahl RL. Use of positron emission tomography in evaluation of brachial plexopathy. Neurology 1994;44:A307.

    Google Scholar 

  72. Ahmad A, Barrington S, Maisey M, Rubens RD. Use of positron emission tomography in evaluation of brachial plexopathy in breast cancer patients. Br J Cancer 1999;79(3–4):478–482.

    Article  PubMed  CAS  Google Scholar 

  73. Cohade C, Osman M, Pannu HK, Wahl RL. Uptake in supraclavicular area fat (“USA-Fat”): description on 18F-FDG PET/CT. J Nucl Med 2003;44(2):170–176.

    PubMed  CAS  Google Scholar 

  74. Tatsumi M, Engles JM, Ishimori T, Nicely O, Cohade C, Wahl RL. Intense (18)F-FG uptake in brown fat can be reduced pharmacologically. J Nucl Med 2004;45(7):1189–1193.

    PubMed  CAS  Google Scholar 

  75. Sugawara Y, Fisher SJ, Zasadny KR, Kison PV, Baker LH, Wahl RL. Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. J Clin Oncol 1998;16(1):173–180.

    PubMed  CAS  Google Scholar 

  76. Griffeth LK, Rich KM, Dehdashti F, Simpson JR, Fusselman MJ, McGuire AH, et al. Brain metastases from non-central nervous system tumors: evaluation with PET. Radiology 1993;186(1):37–44.

    PubMed  CAS  Google Scholar 

  77. Isasi CR, Moadel RM, Blaufox MD. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat 2005;90(2):105–112.

    Article  PubMed  CAS  Google Scholar 

  78. Mortimer JE, Dehdashti F, Siegel BA, Katzenellenbogen JA, Fracasso P, Welch MJ. Positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose and 16-alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res 1996;2(6):933–939.

    PubMed  CAS  Google Scholar 

  79. Dehdashti F, Flanagan FL, Mortimer JE, Katzenellenbogen JA, Welch MJ, Siegel BA. Positron emission tomographic assessment of “metabolic flare” to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med 1999;26(1):51–56.

    Article  PubMed  CAS  Google Scholar 

  80. Wahl RL, Zasadny KR, Hutchins GD, Helvie M, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography (PET): initial evaluation. J Clin Oncol 1993;11(11):2101–2111.

    PubMed  CAS  Google Scholar 

  81. Jansson T, Westlin JE, Ahlstrom H, Lilja A, et al. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? J Clin Oncol 1995;13(6):1470–1477.

    PubMed  CAS  Google Scholar 

  82. Smith IC, Welch AE, Hutcheon AW, Miller IL, Payne S, Chilcott F, et al. Positron emission tomography using [(18)F]-fluorodeoxy-Dglucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000;18(8):1676–1688.

    PubMed  CAS  Google Scholar 

  83. Schelling M, Avril N, Nahrig J, Kuhn W, Romer W, Sattler D, et al. Positron emission tomography using [(18)F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Cin Oncol 2000;18(8):1689–1695.

    CAS  Google Scholar 

  84. Burcombe RJ, Makris A, Pittam M, Lowe J, Emmott J, Wong WL. Evaluation of good clinical response to neoadjuvant chemotherapy in primary breast cancer using [18F]-fluorodeoxyglucose positron emission tomography. Eur J Cancer 2002;38(3):375–379.

    Article  PubMed  CAS  Google Scholar 

  85. Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K, Katzenellenbogen JA, Welch MJ. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 2001;19(11):2797–2803.

    PubMed  CAS  Google Scholar 

  86. Kim SJ, Kim SK, Lee ES, Ro J, Kang S. Predictive value of [18F]FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy. Ann Oncol 2004;15(9):1352–1357.

    Article  PubMed  Google Scholar 

  87. Miller KD, Soule SE, Calley C, Emerson RE, Hutchins GD, Kopecky K, et al. Randomized phase II trial of the anti-angiogenic potential of doxorubicin and docetaxel; primary chemotherapy at Biomarker Discovery Laboratory. Breast Cancer Res Treat 2005;89(2):187–197.

    Article  PubMed  CAS  Google Scholar 

  88. Chen X, Moore MO, Lehman CD, Mankoff DA, Lawton TJ, Peacock S, et al. Combined use of MRI and PET to monitor response and assess residual disease for locally advanced breast cancer treated with neoadjuvant chemotherapy. Acad Radiol 2004; 11(10):1115–1124.

    Article  PubMed  Google Scholar 

  89. Fei X, Wang JQ, Miller KD, Sledge GW, Hutchins GD, Zheng QH. Synthesis of [18F]Xeloda as a novel potential PET radiotracer for imaging enzymes in cancers. Eur J Nucl Med Mol Imaging 2005;32(1):15–22.

    Article  CAS  Google Scholar 

  90. Sun H, Sloan A, Mangner TJ, Vaishampayan U, Muzik O, Collins JM, et al. Imaging DNA synthesis with [18F]FMAU and positron emission tomography in patients with cancer. Eur J Nucl Med Mol Imaging 2005;32(1):15–22.

    Article  PubMed  CAS  Google Scholar 

  91. Smyczek-Gargya B, Fersis N, Dittmann H, Vogel U, Reischl G, Machulla HJ, et al. PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study. Eur J Nucl Med Mol Imaging 2004;31(5):720–724.

    Article  PubMed  Google Scholar 

  92. Rajendran JG, Mankoff DA, O’Sullivan F, Peterson LM, Schwartz DL, Conrad EU, et al. Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 2004;10(7):2245–2252.

    Article  PubMed  CAS  Google Scholar 

  93. Raylman RR, Ficaro EP, Wahl RL. Stereotactic coordinates from ECT sinograms for radionuclide-guided breast biopsy. J Nucl Med 1996;37(9):1562–1567.

    PubMed  CAS  Google Scholar 

  94. Wahl RL, Quint LE, Cieslak RD, Aisen AM, Koeppe RA, Meyer CR. “Anatometabolic” tumor imaging: fusion of FDG PET with CT or MRI to localize foci of increased activity. J Nucl Med 1993;34(7):1190–1197.

    PubMed  CAS  Google Scholar 

  95. Raylman RR, Fisher S, Brown RS, Ethier SP, Wahl RL. Fluorine-18-fluorodeoxyglucose-guided breast cancer surgery with a positronsensitive probe: validation in preclinical studies. J Nucl Med 1995;36(10):1869–1874.

    PubMed  CAS  Google Scholar 

  96. Yap CS, Seltzer MA, Schiepers C, Gambhir SS, Rao J, Phelps ME, et al. Impact of whole-body 18F-FDG PET on staging and managing patients with breast cancer: the referring physician’s perspective. J Nucl Med 2001;42(9):1334–1337.

    PubMed  CAS  Google Scholar 

  97. Weir L, Worsley D, Bernstein V. The value of FDG positron emission tomography in the management of patients with breast cancer. Breast J 2005;11(3):204–209.

    Article  PubMed  Google Scholar 

  98. Eubank WB, Mankoff DA. Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med 2005;35(2):84–99.

    Article  PubMed  Google Scholar 

  99. Bakheet SM, Powe J, Kandil A, Ezzat A, Rostom A, Amartey J. F-18 FDG uptake in breast infection and inflammation. Clin Nucl Med 2000;25(2):100–103.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Johns Hopkins PET Center, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University (JHU) School of Medicine, Baltimore, MD, USA

    Richard L. Wahl MD

Authors
  1. Richard L. Wahl MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Northern California PET Imaging Center, Sacramento, CA, USA

    Peter E. Valk MB, BS, FRACP

  2. Positron Emission Tomography, Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN, USA

    Dominique Delbeke MD, PhD (Professor and Director of Nuclear Medicine) (Professor and Director of Nuclear Medicine)

  3. Department of Nuclear Medicine, Royal North Shore Hospital, Sydney, Australia

    Dale L. Bailey PhD (Associate Professor of Medicine) (Associate Professor of Medicine)

  4. Cancer Imaging and Tracer Development Program, The University of Tennessee Medical Center, Knoxville, TN, USA

    David W. Townsend PhD (Director) (Director)

  5. Department of Radiological Sciences, Guy’s and St Thomas’ Clinical PET Centre, Guy’s and St Thomas’ Hospital Trust, London, UK

    Michael N. Maisey BSc, MD, FRCR, FRCP (Professor of Emeritus) (Professor of Emeritus)

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag London Limited

About this chapter

Cite this chapter

Wahl, R.L. (2006). PET and PET/CT Imaging in Breast Cancer. In: Valk, P.E., Delbeke, D., Bailey, D.L., Townsend, D.W., Maisey, M.N. (eds) Positron Emission Tomography. Springer, London . https://doi.org/10.1007/1-84628-187-3_13

Download citation

  • DOI: https://doi.org/10.1007/1-84628-187-3_13

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-85233-971-5

  • Online ISBN: 978-1-84628-187-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation